Scarica l'app Stockscreener
20.69
4.48%
-0.97
Dopo l'orario di chiusura:
20.40
-0.29
-1.40%
Precedente Chiudi:
$21.66
Aprire:
$21.02
Volume 24 ore:
173.53K
Relative Volume:
1.07
Capitalizzazione di mercato:
$322.23M
Reddito:
$925.00K
Utile/perdita netta:
$-90.35M
Rapporto P/E:
-4.3919
EPS:
-4.7109
Flusso di cassa netto:
$-78.52M
1 W Prestazione:
-3.36%
1M Prestazione:
-0.24%
6M Prestazione:
-1.38%
1 anno Prestazione:
+97.80%
Intervallo 1D:
$19.87
$22.08
Intervallo di 1 settimana:
$19.10
$22.44
Portata 52W:
$6.875
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Nome
Neurogene Inc
Settore
Industria
Telefono
(877) 237-5020
Indirizzo
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
20.69 | 322.23M | 925.00K | -90.35M | -78.52M | -4.7109 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Craig Hallum | Buy |
| 2025-05-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2024-03-21 | Iniziato | William Blair | Outperform |
| 2024-01-08 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-05 | Iniziato | Stifel | Buy |
| 2024-01-04 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Neurogene Inc Borsa (NGNE) Ultime notizie
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Institution Moves: Is Neurogene Inc stock risky to hold nowQuarterly Performance Summary & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Neurogene (NGNE) president and CFO Cvijic sells $55k in stock - Investing.com Canada
Neurogene (NGNE) CFO’s 2,558-share sale tied to mandatory RSU tax withholding - Stock Titan
Neurogene (NGNE) CEO McMinn logs small, tax-related sale after RSU vesting - Stock Titan
RSU tax sale: Neurogene (NGNE) CMO disposes 828 shares - Stock Titan
Pullback Watch: Will Neurogene Inc stock hit new highs in YEARTrade Risk Assessment & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Equities Analysts Set Expectations for Neurogene Q1 Earnings - marketbeat.com
Neurogene (NGNE) Receives a Buy from LifeSci Capital - The Globe and Mail
HC Wainwright Weighs in on Neurogene FY2027 Earnings - Defense World
Neurogene (NGNE) price target increased by 37.29% to 82.62 - MSN
Brokers Issue Forecasts for Neurogene FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
H.C. Wainwright reiterates Neurogene stock rating at buy, $70 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Neurogene stock rating at buy, $70 target - Investing.com
Q1 Earnings Estimate for Neurogene Issued By Lifesci Capital - MarketBeat
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE) - The Globe and Mail
Neurogene (NASDAQ:NGNE) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS - marketbeat.com
Neurogene: Q4 Earnings Snapshot - theheraldreview.com
Neurogene Inc. Advances Gene Therapy for Rare Neurological Diseases with EXACT Platform and NGN-401 Clinical Development - Minichart
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Neurogene 10-K: Revenue $0.0M, EPS $(4.24) on $90.4M net loss - TradingView
Neurogene (NASDAQ: NGNE) details Rett gene therapy progress and cash runway - Stock Titan
Neurogene Reports Positive Interim Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome and Advances Toward Commercialization in 2026 - Minichart
William Blair reiterates Neurogene stock rating on trial progress - uk.investing.com
William Blair reiterates Neurogene stock rating on trial progress By Investing.com - Investing.com India
Leerink reiterates Neurogene stock rating on Rett syndrome progress By Investing.com - Investing.com Australia
Leerink reiterates Neurogene stock rating on Rett syndrome progress - Investing.com
Neurogene Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Neurogene : Corporate Presentation March 2026 - marketscreener.com
NGN-401 clinical developments and financials drive Neurogene Inc. corporate update - Traders Union
Neurogene full yr net loss widens on higher R&D costs - TradingView
NGNE: NGN-401 advances with full trial enrollment, FDA Breakthrough status, and strong cash runway - TradingView
Neurogene (NGNE) deepens Rett gene therapy push with 2025 loss and long cash runway - Stock Titan
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates - marketscreener.com
BRIEF-Neurogene FY Operating Expenses USD 103.328 Million - TradingView
Rett syndrome gene therapy clears 50% dosing, no HLH cases yet - Stock Titan
Neurogene Inc.: Fundamental Analysis and Financial Ratings | | US64135M1053 - marketscreener.com
If You Invested $1,000 in Neurogene (NGNE) - Stock Titan
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference - MarketBeat
Neurogene Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
Neurogene Inc: chief scientific officer Cobb sells $141k in stock - Investing.com Australia
Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 4,045 Shares of Stock - MarketBeat
Neurogene (NASDAQ:NGNE) Insider Sells 6,797 Shares - MarketBeat
Neurogene (NGNE) CSO sells 6,797 shares under 10b5-1 plan - stocktitan.net
Tax-driven share sale by Neurogene (NGNE) president and CFO disclosed - Stock Titan
Neurogene Inc Azioni (NGNE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):